Dr. Shrikant Mishra

Technologist | Novelist | Poet
  • Chief Scientific Officer, D.B.L. Enterprise, Vadodara
  • Founder of Loohana Oceania Pvt Ltd, Loohana Electrica Pvt Ltd, Mentor of 100 Cube, IIT Bhubaneswar
  • Professor and Head Technology and Translation Research, Kiit School of Biotechnology, Bhubaneswar

Current On Going Research (2023-24):

Working with MTech pharma students on In silico modeling criteria for gut microbiome metabolites in drug discovery for neurological disorders, Target id and validation environment for migraine, Specificity and sensitivity of flow Elisa in bed side detection of osteoarthritis, Mechanism of in vivo immune escape of tumor cells exposed to CDK 4,6 inhibitor, RNA secondary structure and expression levels in rosette origami cells, siRNA formulation method development and validation criteria, a QA perspective, on role of stromal cells, platelets, memory B cells, and dendritic cells in retrovial infection, drug related: receptor targets, comparative pK/PD profile, drug-drug interaction for retroviral drugs, virus related: transcription and translation mechanisms of retroviruses, packaging of retroviruses, stem cell therapy in Covid-19, Exosome therapy, and Gene Editing in Cell Therapy of Solid Tumors. Long term toxicity in zebrafish.

Current On Going Research (2021-22):

Working with MTech pharma students on role of stromal cells, platelets, memory B cells, and dendritic cells in retrovial infection, drug related: receptor targets, comparative pK/PD profile, drug-drug interaction for retroviral drugs, virus related: transcription and translation mechanisms of retroviruses, packaging of retroviruses, stem cell therapy in Covid-19, Exosome therapy, and Cell therapy of cancers.

Teaching Strength

Books Published

(Click on image for more information)

Check Out My Work

(Click on image for more information)

Teriperatide
Teriperatide
Bivalirudine
Bivalirudine
Eptifibatide
Neulasta
Neulasta
Somatropin
Somatropin
Octereotide
Octereotide
  • ORF optimization for E coli and mammalian expression (RNA secondary structure, enthalpy), Generation of E coli MCB (master cell bank) and clone validation, Generation of mammalian MCB and clone validation
  • Special assays : G-PCR assays, clonogenic assays, kinase assays, check point assays, SPR assays. Novel discovery bioassay development (platforms : cell culture, ELISA, fluorescence, flow cytometry, radioactive)
  • Fermentation batch validation (pcd, volumetric production, O2, pH, Temp, anti-foam, acetate), High level soluble expression / targeted expression, Trouble shooting ion-exchange chromatography, HIC, GPC, EBA, and HPLC (method development, critical parameters, chromatographic scale up, and validation)
  • Trouble shooting analytical method development and validation (sds-page, western blot, southern blot, PCR, 2D western, TLC, HPLC, LC-MS etc.), Forced degradation, half life, and Potency validation
  • Trouble shooting formulation method development and validation, Technology Transfer
  • CBSE, Bharatiya Vidya Bhavan, Kasturba Gandhi Marg, New Delhi, 1977
  • BSc Physics, St Stephen’s College, Delhi University, 1980
  • MSc Physics, St. Stephen’s college, Delhi University, 1982
  • Instructor, St. Stephen’s college, Delhi University, 1983-4
  • Instructor, Hindu college, Delhi University1984-5
  • Instructor, Regional College Of Engineering, Bhubaneswar, Odisha1985
  • Instructor, Maharshi College, Bhubaneswar, Odisha 1985
  • Graduate Student, Biochemistry, Virginia Maryland Regional College Of Veterinary Medicine, Virginia Tech, U.S.A 1986
  • Research Fellow, Virginia Maryland Regional College Of Veterinary Medicine, Virginia Tech, U.S.A 1992
  • Research Fellow, University of Maryland Cancer Center, U.S.A 1993
  • Senior Fellow, Mayo Clinic, U.S.A 1994
  • Head, Biotechnology Research Laboratory, USV Ltd, India(1996-2010)
  • Consultant, Sun Pharmaceuticals, Vadodara, India (2011-13)
  • Head, Technology Translation Research Laboratory, Kiit School Of Biotechnology, Bhubaneswar, India(2013-present)
  • Chief Scientific Officer, D.B.L. Enterprise, Vadodara
  • Founder, Loohana Oceania Pvt Ltd, Loohana Electrica Pvt Ltd, Loohanatech Allianz, 100 Cube, IIT Bhubaneswar

  • CART  Therapy Product——————————–(Enquire)
  • Clopidrogel ——————————————-Anti-platelet/Delivered aggregation assay system for marketed samples
  • Famcyclovir——————————————-For herpes/Product and process developed at 1.0 kg , lab scale
  • Simvastatin——————————————-Anti-cholesterol/Product developed from lovatatin at 1.0 kg, lab scale
  • Acarbose———————————————-Obesity/From clone to process at 1 lit
  • Eptifibatide——————————————–Anti-platelet/From lab to launch, produced by solid phase synthesis
  • Bivalirudine——————————————-Anti-platelet /From lab to launch , produced by solid phase synthesis
  • Octreotide———————————————Anti-cancer/From lab to launch , produced by solid phase synthesis
  • hGH—————————————————–Turner’s syndrome/From clone to human phase III
  • G-CSF—————————————————Anti-cancer/From clone to pre-clinical, animal
  • PEG-G-CSF———————————————Anti-cancer/From clone to pre-clinical, animal
  • PTH——————————————————Osteoporosis/From clone to human phase III
  • PDGF—————————————————-Diabetes / topical/From clone to human phase III
  • Neseritide——————————————— CHF/From clone to human phase III
  • IL-2——————————————————-Anti-cancer/From clone to scale up
  • Lucentis————————————————-Macular degeneration/Clone to R&D process
  • Aranesp————————————————-Anemia/Cloned development
  • Two component sanitizer—————————Sanitizer, d-odorizer/Completed product and technology development
  • MEG-CO feel——————————————Anti-flu/Completed product and technology development
  • IMAK—————————————————-Anti-pain/Completed product and technology development

96% in MCATs (all USA examination), GRE Verbal: 151/170, GRE Quant: 159/170. Vector-Host Platforms in E Coli and CHO systems, Cloned ~ 52 genes in E. Coli platform, Cloned ~ 34 genes in CHO platform, ~ 15 years of industry experience, ~ 31 years of biotechnology experience, 24 International Patents, 34 International Publications, 3 books published, 17 MTech Thesis , 5 Industry related theory courses  for MTech, Biotechnology,  3 Industry related practical courses for MTech, Biotechnology, 4 products crossed human phase-III trials,  12 products technologies developed end to end,  3 synthetic peptide products in ICU (Eptifibatide, Bivalirudine, Octreotide), ~ 500 analytical / bio analytical methods scaled up. Products delivered end to end being : rhG-CSF, PEG-G-CSF, Eptifibatide,  Octreotide, Bivalirudine, rEK, , rHGH, rPTH(1-34). Train more than 150 MTech students per year (2013-present). As Head Of Research Took company from 127 Cr to 1500 Cr in 14 years. Seven products delivered end to end in the clinic ( three in ICU), 1500 students into the market.

  • Products Delivered to the clinic : rhG-CSF, PEG-G-CSF, Eptifibatide, Octreotide, Bivalirudine, rEK, rHGH, rPTH(1-34)
  • Marketted Products : rhG-CSF, PEG-G-CSF, Eptifibatide,  Octreotide, Bivalirudine, rEK.
  • Clinical Trial (human Phase III): recombinant hGH, recombinant PTH(1-34), rhPDGF-BB, rh Neseitide
  • Approved preclinical Trials : recombinant hG-CSF (India), recombinant PEG-G-CSF (EU)
  • Mesenchymal stem cells therapy in the control of long-term organ toxicity in COVID-19 infection (Asian J. of Pharmaceutical Sciences. Submitted, 2022)
  • Exosomes manufacturing and development (MTech Thesis,  May  2022)
  • Validation environment of mesenchymal stem cells. ( MTech Thesis,  May  2021)
  • Comparative Quality assurance of Moderna and Pfizer Covid-19 vaccines. (MTech Thesis,  May  2021)
  • Comprehensive study on substance abuse and addiction in subjects to develop promising targets and novel pharmacotherapy targets to treat SUDs. (MTech Thesis,  May  2020)
  • Why do anti-fungals fail at primary phase ( MTech Thesis, May 2020)
  • A Rapid Drug Sensitivity Evaluation  For  Azithromycin In Patients (MTech Thesis, April 2019)
  • Mechanism of Kanamycine drug resistance (MTech Thesis, April 2019)
  • QSAR of ZAP 70 Signalling (MTech Thesis, April 2018)
  • Relevance of pre-grant opposition to project management (MTech Thesis, April 2018)
  • Designing a protocol to increase Shelf Life (MTech Thesis, April 2018)
  • Field stability tests for polymeric container closure (MTech Thesis, April 2018)
  • Relevance of pre-grant opposition to start ups  ( MTech Thesis , April 2017 )
  • Topical formulation for viral infection, MEG-Co-feel ( MTech Thesis ,April 2015)
  • Novel topical formulation for neuro and muscular pain, IMAK ( MTech Thesis ,April 2015)
  • Of Regulated Bio-marker Platforms , p62, 1st International Conference On Translational Research, from basic science to clinical application (2015)
  • Patent Application (2015, submission date : 07/02/2015) : Two components skin sanitizing/moisturizing system
  • US20090035815: Synthetic Gene For Enhanced Expression In E. Coli
  • WO2009019715: Novel Orthogonal Process For Purification Of Recombinant Human Parathyroid Hormone (Rhpth) (1 34)
  • WO2009005973:Synthetic Gene For Enhanced Expression In E.Coli
  • WO2008136014: Cloning And Expression Of Enterokinase And Its Process For Production
  • US20070249806: Solid Phase Fmoc Chemistry Process To Prepare Peptides
  • KR1020070083387: A Novel Process For Purification Of Human Growth Harmone
  • CA2641372: Affinity Polypeptide For Purification Of Recombinant Proteins KR20070094902:Low Cell Density Fermentation Process For The Production Of Heterologous Recombinant Proteins In Microorganisms
  • KR20070083387: A Novel Process For Purification Of Human Growth Hormone
  • EP1758933: Chimeric Human Growth Hormone Derived From The Placenta And Pituitary Isoform And Processes For Obtaining Said Chimera
  • WO2006051554: A Novel Process For Purification Of Human Growth Hormone
  • CA2589716: Low Cell Density Fermentation Process For The Production Of Heterologous Recombinant Proteins In Microorganisms
  • CA2565209: A Novel Process For Purification Of Human Growth Hormone
  • CA25 AU2004324756: A Novel Process For Purification Of Human Growth Hormone
  • AU2004320986: Chimeric Human Growth Hormone Derived From The Placenta And Pituitary Isoform And Processes For Obtaining Said Chimera
  • 60007: Process For The Preparation Of Peptides
  • AU2004320599: Process For The Preparation Of Peptides
  • WO2006001027: Chimeric Human Growth Hormone Derived from the Placenta and Pituitary Isoform and Process for obtaining the same.
  • WO 2006/05/554 : A Novel Process For Purification of Human Growth Hormone
  • WO 2006067793 : Low Cell Density Fermentation Process for the production of Hetrologous Recombinant protein in Microorganisms.
  • WO2005121164 : A process for the preparation of peptides
  • WO2007096899: Affinity Polypeptide for Purification of recombinant protein
  • US2007249806 : Solid Phase FMOC Process to Prepare Peptides
  • PCT/IN/2007/000277 : Cloning and expression of enterokinase and it’s process for production
  • 247 / MUM/2007 : Synthetic gene for enhanced expression in E. Coli
  • 1543 / MUM/2007/ : Novel orthogonal process for the purification of recombinant human parathyroid hormone rhPTH (1-34)
  • 1776/MUM/2007: An improved process for FMOC synthesis of Ecosapeptide
  • Association of inhibition of cell growth by O-phospho-L-Tyr with decreased tyrosine phosphorylation.. Cancer Letters. 1996, 102(1-2): 65-71
  • A microtiter assay for Cu/Zn and Mn- superoxide dismutase. Ind. J. Biochem. Biophys. 1996 (vol 33, 1996, pp319-322)
  • A spin decay assay for tumor necrosis factor cytoxicity. Ind. J. Biochem. Biophys. 32, 254-260, 1995
  • Regulation of the suspected tumor suppressor gene product CLP in human breast epithelial cells. J. Cell. Biochem. 18 (Supp):171
  • Regulation of expression and search for specific tumor suppressor gene product. Mini paper, 3rd European Symp. On Ca Binding Proteins. Zurich, Switzerland, march 6-9, 1994
  • Modulation of the cytotoxicity activity of tumor necrosis factor by protein tyrosine kinase and protesin tyrosine phosphatise inhibitors. Lymphokine & cytokine Research. 13(2), 77-83, 1994.
  • Interferon –gamma induced reduction in erb B-2 Tyrosyl Phosphorylation in human ovarian carcinoma cells. Int. J. Cancer, 58, 538-542, 1994.
  • A case of recurrent eclampsia.Post grad. Med. J. 1994, 70(828):769.
  • A microtiter enzyme linked immunosorbent assay for protein tyrosine phosphatise. Biochem. Biophys. Acta. 1157: 93-101, 1993.
  • Exogenous phosphotyrosine modulates epidermal growth factor receptor tyrosine phosphorylation. Carcinogenisis 14 : 273, 1993
  • O-Phospho-L-Tyr inhibits cell growth by activating protein tyrosine phosphatises. Cancer Research. 53 : 557-563, 1993.
  • Role of intracellular Ca++ in the epidermal growth factor induced inhibition of protein tyrosine phosptahaase activity in a breast cancer cell line. Biochem. Biophys. Res. Commun., 191: 1065-1072, 1993.
  • Interferon enhancement of tyrosine phosphorylation of epidermal growth factor receptors in human breast carcinoma cells. Anticancer Res. 13, 613-618, 1993.
  • O-phospho-L-tyr inhibits cellular growth by activating protein tyrosine phosphatises. Keystone Symposia on Signalling, Keystone , CO, 1993
  • Preclampsia J. Perinatol, 1993, 13(5): 417-8
  • Regulation of suspected tumor suppressor gene product CLP in human breast epithelial cells. Keystone Symposia on Tumor Suppressor Genes. Taos, NM, 1994
  • O-phospho-L-tyr inhibits cellular growth by activating protein tyrosine phosphatises.J. Cell. Biochem. Suppl. 17A, BZ 624, 1993
  • Regulation of tyrosine phosphorylation of epidermal growth factor in breast cancer cell lines by gamma-interferon.  Proceedings of 83rd Annual Meeting of the American Association for Cancer Research 33: 3(14), 1992.
  • Microtiter enzyme linked immunosorbent assay for protein tyrosine phosphatise. World Congress of Cell and tissue Culture Washington DC, 1992.
  • Mechanism of TNF-alpha cytotoxicity in a retrovial transformation model. Ph.D Thesis ( 1991)
  • Tumor necrosis factor modulates tyrosine phosphorylation of A-MuLV specific cell surface antigen. 7251, FASEB J. 5(6): 1619, 1991.
  • EPR observation of TEMPO quenching in monitoring TNF alpha cytotoxicity in L929 cells. Rocky Mountain Conference on Analytical Chemistry, 1991.
  • Role of free radicals during reperfusion injury in isolated rat lungs. American Physiological Society Conference Proceedings, 1990.
  • Reversal of superoxide dismutase reaction as detected by EPR spin trapping techniques. Conference proceedings of Federation of American Society of Experimental Biology. 2115, 1990.
  • Regulation of manganese superoxide dismutase in endothelial cells. J. Cell. Biol. 107: 217a, 1989.
  • Mechanism of microwave induced membrane damage in human erythrocytes. J. cell. Biol. 107, 188a, 1989
  • Broken symmetry of biomolecules. Biophysical. J. , 151; 96a, 1987.    

Member, Bhavanite, Bharatya Vidya Bhavan Alumni(1977-current)

Member, St. Stephens College Alumni(1982-current)

Member, Mayo Clinic Alumni(1994-current)

Member, Indian Science Congress (2013-present)

Jury, Biotech Projects, Confederation Of Indian Industries (C.I.I)(2013-current)

Advisor, Technology Commercialization Facilitation Agency (T.C.F.A) (2013-current)

Chief Scientific Advisor, E.O. Bio Pvt Ltd. (2022-present)

Lockheed’s Martin Talent Network (2022- present)

Mentor, KIIT Animal and Environment Welfare Society (2022- present)

Amgen Talent (2019—present)

Moderator, Express Pharma, Dec 2021

Editorial Board, IJPPT, 2021-present

Editorial Board, CCLSJ, 2021-present

Represented India in “ICONBACC 2021, Misamis University, Philippines

Selection Committee member, Pantheon Award, 2021

Amgen Talent (2019—present)

Moderator, Express Pharma, Dec 2021

Editorial Board, IJPPT, 2021-present

Editorial Board, CCLSJ, 2021-present

Represented India in “ICONBACC 2021, Misamis University, Philippines

Selection Committee member, Pantheon Award, 2021

Recipient of Biotechnology Ignition Grant (BIG) for multi-drug resistance (2014-current)

Recipient of MSME Award for development of culture media for CHO DG44 cells ( 2013-Current)

Jury, Biotech Projects, Confederation Of Indian Industries (C.I.I)(2013-current)

Advisor, Technology Commercialization Facilitation Agency (T.C.F.A) (2013-current)

Member, Indian Science Congress (2013-present)

Head, Technology & Translational Research, KIIT-TBI, KIIT University, Bhubaneswar, Orissa (2013-current)

Consulting Director Position Offer, Intas Pharmaceuticals Ltd.

Consultant , Sun Pharmaceuticals Ltd.(2010-11)

General Manager, Biotechnology Research Laboratory, USV.(1995-2010)

Member, Mayo Clinic Alumni(1994-current)

Swiss Post Doctoral Fellowship, 1993-4

Instructor, Genetics, Virginia Tech (1991)

NIH Postdoctoral Fellowship, 1992-3

NIH Graduate Fellowship, 1986-91

Member, St. Stephens College Alumni(1982-current)

Member, Bhavanite, Bharatya Vidya Bhavan Alumni(1977-current)

Long Service Award : USV Ltd. ( 1996-2006)

Tata Endowment Scholar 1986

Dept. Of Atomic Energy Fellowship BARC (1983-1985)

Instructor, Physics, St. Stephen’s College, Delhi University ( 1982)

Instructor, Physics, Hindu College, Delhi University(1983)

National Science Scholarship ( 1980-1982)

School topper, Kulpati K.M. Munshi Gold Medal For Science(1977)

School captain, BVB Public School, Kasturba Gandhi Marg, (1976-77)

Letters Of Appreciation from Nobel Laureate, and President Of U.S.A

Letter Of Appreciation from Center For Disease Control, USA

@ E.O Bio Pvt Ltd (Genome editing of immune cells for anti-cancer regimen of solid tumors, 2022- present)

@ KIM’s Hospital, BBSR (In vitro model of sepsis, role of topoisomerase inhibitors, DNA gyrase inhibitors, 30 S subunit inhibition, and 50 S subunit inhibition, 2022-present)

@ UCSF (Platform troubleshoot2021-present)

@ Start up (CART Therapy platform)

* If you have health anxiety write to us @: yourtearsmine@gmail.com

(stories in blog)

Scroll to Top